Published in Antimicrob Agents Chemother on November 01, 1997
Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection | NCT00388167
Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev (1999) 12.90
Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol (1998) 7.01
Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother (2005) 4.89
Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother (1997) 4.87
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev (2008) 3.52
Combination antifungal therapy. Antimicrob Agents Chemother (2004) 3.49
In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother (2001) 3.28
In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother (2003) 2.92
In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother (2000) 2.73
Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother (1997) 2.73
Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother (2002) 2.68
In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother (2002) 2.67
The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother (2002) 2.60
Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother (2000) 2.51
Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother (2000) 2.50
Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. J Clin Microbiol (2004) 2.31
Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother (2002) 2.30
Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob Agents Chemother (2003) 2.27
Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother (2002) 2.26
Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother (2005) 2.08
Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother (2005) 2.07
Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J Clin Microbiol (2003) 1.89
Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother (2004) 1.86
Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. J Infect Dis (2008) 1.82
Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob Agents Chemother (2007) 1.77
Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J Clin Microbiol (2003) 1.75
Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. J Clin Microbiol (2001) 1.74
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell (2008) 1.73
Disk diffusion method for determining susceptibilities of Candida spp. to MK-0991. J Clin Microbiol (1999) 1.67
In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother (2002) 1.65
A glucan synthase FKS1 homolog in cryptococcus neoformans is single copy and encodes an essential function. J Bacteriol (1999) 1.65
In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol (2002) 1.64
Combination treatment of invasive fungal infections. Clin Microbiol Rev (2005) 1.59
Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother (2005) 1.57
Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. Antimicrob Agents Chemother (2004) 1.48
How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in Cryptococcus neoformans. Annu Rev Microbiol (2009) 1.43
Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrob Agents Chemother (2001) 1.35
Chemosensitization of fluconazole resistance in Saccharomyces cerevisiae and pathogenic fungi by a D-octapeptide derivative. Antimicrob Agents Chemother (2004) 1.34
Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Antimicrob Agents Chemother (2006) 1.34
Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins. Antimicrob Agents Chemother (2005) 1.28
Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Chemother (2005) 1.25
Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother (2006) 1.24
Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis (2004) 1.23
Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother (1998) 1.15
FKS1 mutations responsible for selective resistance of Saccharomyces cerevisiae to the novel 1,3-beta-glucan synthase inhibitor arborcandin C. Antimicrob Agents Chemother (2004) 1.15
Elevated chitin content reduces the susceptibility of Candida species to caspofungin. Antimicrob Agents Chemother (2012) 1.11
Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob Agents Chemother (2000) 1.10
Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus. Antimicrob Agents Chemother (2000) 1.08
Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii. Antimicrob Agents Chemother (2006) 1.08
Caspofungin in combination with amphotericin B against Candida parapsilosis. Antimicrob Agents Chemother (2006) 1.04
In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob Agents Chemother (2003) 1.01
Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata. Antimicrob Agents Chemother (2005) 1.00
Comparison of echinocandin antifungals. Ther Clin Risk Manag (2007) 0.99
Coccidioides posadasii contains a single 1,3-beta-glucan synthase gene that appears to be essential for growth. Eukaryot Cell (2005) 0.94
Conidial viability assay for rapid susceptibility testing of Aspergillus species. J Clin Microbiol (2002) 0.93
Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother (2010) 0.89
Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother (2004) 0.89
Pharmacokinetics and safety of intravitreal caspofungin. Antimicrob Agents Chemother (2014) 0.88
Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment. J Clin Microbiol (2011) 0.88
Stage-specific innate immune recognition of Aspergillus fumigatus and modulation by echinocandin drugs. Med Mycol (2008) 0.85
Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species. Antimicrob Agents Chemother (2016) 0.84
New methods to assess susceptibilities of Aspergillus isolates to caspofungin. J Clin Microbiol (2003) 0.84
Effect of fluid loading during hypovolaemic shock on caspofungin pharmacokinetic parameters in pig. Crit Care (2011) 0.81
Susceptibility testing of Candida albicans isolated from oropharyngeal mucosa of HIV(+) patients to fluconazole, amphotericin B and Caspofungin. killing kinetics of caspofungin and amphotericin B against fluconazole resistant and susceptible isolates. Braz J Microbiol (2009) 0.81
What's New in Antifungals? Curr Infect Dis Rep (2003) 0.81
Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata. Antimicrob Agents Chemother (2009) 0.80
Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database. Antimicrob Agents Chemother (2010) 0.80
Sequential therapy with caspofungin and fluconazole for Candida albicans infection. Antimicrob Agents Chemother (2004) 0.78
Saccharomyces cerevisiae biofilm tolerance towards systemic antifungals depends on growth phase. BMC Microbiol (2014) 0.77
Caspofungin: the first agent available in the echinocandin class of antifungals. Proc (Bayl Univ Med Cent) (2002) 0.77
Evaluating retinal toxicity of intravitreal caspofungin in the mouse eye. Invest Ophthalmol Vis Sci (2010) 0.77
Effect of the echinocandin caspofungin on expression of Candida albicans secretory aspartyl proteinases and phospholipase in vitro. Antimicrob Agents Chemother (2002) 0.77
Treatment and prophylaxis of invasive candidiasis. Semin Perinatol (2012) 0.76
In vitro activity of A-192411.29, a novel antifungal lipopeptide. Antimicrob Agents Chemother (2000) 0.75
Anidulafungin and its role in candida infections. Infect Drug Resist (2009) 0.75
In Vitro Activity of Caspofungin Against Fluconazole-Resistant Candida Species Isolated From Clinical Samples in Iran. Jundishapur J Microbiol (2015) 0.75
Albumin Enhances Caspofungin Activity against Aspergillus Species by Facilitating Drug Delivery to Germinating Hyphae. Antimicrob Agents Chemother (2015) 0.75
Creation, characterization and utilization of Cryptococcus neoformans mutants sensitive to micafungin. Curr Genet (2017) 0.75
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1992) 12.13
Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother (1994) 6.45
Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother (1997) 4.87
Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother (1993) 4.04
Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis (1989) 4.01
Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol (1994) 3.51
Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis (1989) 3.14
Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis. Antimicrob Agents Chemother (1994) 2.99
Hospital-acquired infections: diseases with increasingly limited therapies. Proc Natl Acad Sci U S A (1994) 2.87
Compounds active against cell walls of medically important fungi. Clin Microbiol Rev (1993) 2.67
Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother (1995) 2.62
Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis (1994) 2.41
In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin. Antimicrob Agents Chemother (1992) 2.39
New spectrum of fungal infections in patients with cancer. Rev Infect Dis (1989) 2.16
Fluconazole-resistant Candida albicans. Clin Infect Dis (1993) 2.10
Cell-wall glucans of Cryptococcus neoformans Cap 67. Carbohydr Res (1990) 2.08
In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) against Aspergillus and Candida species. Eur J Clin Microbiol Infect Dis (1990) 2.06
Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fumigatus (1,3)-beta-D-glucan synthase. FEMS Microbiol Lett (1993) 1.74
Detection of mycotoxins by thin-layer chromatography: application to screening of fungal extracts. Appl Microbiol (1970) 6.40
Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother (1997) 4.87
Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother (1997) 4.14
Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives. J Med Chem (1994) 3.52
Mycotoxins (ochratoxin A, citrinin, and sterigmatocystin) and toxigenic fungi in grains and other agricultural products. J Agric Food Chem (1973) 3.21
Red cell distribution width, haemoglobin A1c and incidence of diabetes mellitus. J Intern Med (2014) 2.85
Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother (1997) 2.73
Brine shrimp (Artemia salina L.) larvae as a screening system for fungal toxins. Appl Microbiol (1971) 2.72
comK encodes the competence transcription factor, the key regulatory protein for competence development in Bacillus subtilis. Mol Microbiol (1995) 2.68
Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother (2001) 2.65
Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother (1995) 2.62
Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis (1998) 2.61
Mycotoxins from food-borne fungi. Can J Microbiol (1968) 2.61
A role in vivo for tumor necrosis factor alpha in host defense against Chlamydia trachomatis. Infect Immun (1990) 2.55
Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother (2000) 2.51
Gas chromatography with electron capture and mass spectrometric detection of deoxynivalenol in wheat and other grains. J Assoc Off Anal Chem (1981) 2.40
In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin. Antimicrob Agents Chemother (1992) 2.39
In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373. Antimicrob Agents Chemother (1995) 2.37
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis (2008) 2.25
Fibroblast growth factor 2 control of vascular tone. Nat Med (1998) 2.21
Red blood cell distribution width is associated with incidence of atrial fibrillation. J Intern Med (2013) 2.10
Treatment of lymphedema with a multicompartmental pneumatic compression device. J Am Acad Dermatol (1989) 2.04
A double-blind crossover comparison of topical anesthetics. J Am Dent Assoc (1979) 1.98
Penicillium viridicatum Westling: a new source of ochratoxin A. Can J Microbiol (1969) 1.84
The regulation of competence transcription factor synthesis constitutes a critical control point in the regulation of competence in Bacillus subtilis. J Bacteriol (1994) 1.82
Localisation of haematuria by red cell analysers and phase contrast microscopy. Nephron (1989) 1.81
Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates. Antimicrob Agents Chemother (1997) 1.80
Risk assessment of the mycotoxin zearalenone. Regul Toxicol Pharmacol (1987) 1.75
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother (2000) 1.66
Antipneumocystis activity of water-soluble lipopeptide L-693,989 in rats. Antimicrob Agents Chemother (1992) 1.57
SLE-like autoantibodies and Sjögren's syndrome-like lymphoproliferation in TGF-beta knockout mice. J Immunol (1995) 1.57
Role of CD8 T cells in primary Chlamydia infection. Infect Immun (1995) 1.56
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Formation of aflatoxins by Aspergillus ostianus Wehmer. Appl Microbiol (1967) 1.55
Autonomous replication in human cells of multimers of specific human and bacterial DNA sequences. Mol Cell Biol (1993) 1.54
Elongation factor 2 as a novel target for selective inhibition of fungal protein synthesis. J Biol Chem (1998) 1.53
Effect of acetylsalicylic acid on lysosomes. Proc Soc Exp Biol Med (1966) 1.52
Ceruloplasmin and atrial fibrillation: evidence of causality from a population-based Mendelian randomization study. J Intern Med (2013) 1.47
Erythema ab igne: a histopathological study. J Invest Dermatol (1966) 1.46
Use of a temporary screw for alignment and fixation of sagittal mandibular condylar fractures with lateral screws. Int J Oral Maxillofac Surg (2010) 1.45
Consecutive outbreaks of epizootic haemorrhagic disease of deer and bluetongue. Vet Rec (1988) 1.44
Searches for Lepton flavor violation in the decays tau{+/-}-->e{+/-}gamma and tau{+/-}-->mu{+/-}gamma. Phys Rev Lett (2010) 1.44
Butorphanol and nalbuphine: a pharmacologic comparison. Oral Surg Oral Med Oral Pathol (1985) 1.43
Formation of trichothecenes by Fusarium solani var. coeruleum and Fusarium sambucinum in potatoes. Appl Environ Microbiol (1984) 1.43
Common genetic variation near the connexin-43 gene is associated with resting heart rate in African Americans: a genome-wide association study of 13,372 participants. Heart Rhythm (2012) 1.43
Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression. J Clin Invest (1996) 1.42
Risk assessment of the mycotoxin ochratoxin A. Biomed Environ Sci (1989) 1.40
Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy. Med J Aust (1997) 1.40
A comparative study of the skeletal morphology of the temporo-mandibular joint of children and adults. J Postgrad Med (2008) 1.39
T-lymphocyte subsets in acute illness. Crit Care Med (1995) 1.39
Screening surgeons for HIV infection. A cost-effectiveness analysis. Ann Intern Med (1995) 1.38
Postoperative radiotherapy for Dukes' B and C rectal cancer: Peter MacCallum Cancer Institute experience. Australas Radiol (1996) 1.38
Analysis of blue cheese for roquefortine and other alkaloids from Penicillium roqueforti. J Agric Food Chem (1976) 1.38
Prospective observational study of acute coronary syndromes in China: practice patterns and outcomes. Heart (2007) 1.36
Screening Fusarium strains isolated from overwintered Canadian grains for trichothecenes. Mycopathologia (1980) 1.35
Chlamydia trachomatis pneumonia induces in vivo production of interleukin-1 and -6. Infect Immun (1992) 1.33
Naloxone-associated morbidity and mortality. Oral Surg Oral Med Oral Pathol (1981) 1.30
Study of conditions of production of roquefortine and other metabolites of Penicillin roqueforti. Appl Environ Microbiol (1977) 1.30
Occurrence of patulin in apple juice. J Agric Food Chem (1972) 1.27
The economic burden of global blindness: a price too high! Br J Ophthalmol (1996) 1.26
Inhibition of ADAMTS-7 and ADAMTS-12 degradation of cartilage oligomeric matrix protein by alpha-2-macroglobulin. Osteoarthritis Cartilage (2008) 1.26
Netherton's syndrome: a syndrome of elevated IgE and characteristic skin and hair findings. J Allergy Clin Immunol (1995) 1.25
VEGF gene expression is upregulated in electrically stimulated rat skeletal muscle. Am J Physiol (1995) 1.24
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Application of peroxidase labelled antibody assays for detection of porcine IgG antibodies to hog cholera and bovine viral diarrhea viruses. J Virol Methods (1989) 1.22
Hydrocarbons of Biological Origin from a One-Billion-Year-Old Sediment. Science (1964) 1.22
The quantitative separation of 3',5'-cyclic adenosine monophosphate, adenosine-5'-monophosphate, adenosine-5'-diphosphate, and adenosine-5'-triphosphate by ion-exchange chromatography on diethylaminoethyl sephadex. J Chromatogr (1970) 1.22
Early clinical experience with a hybrid bioartificial liver. Scand J Gastroenterol Suppl (1995) 1.21
Toxins of molds from decaying tomato fruit. Appl Environ Microbiol (1979) 1.20
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
Development and characterization of Histoplasma capsulatum-reactive murine T-cell lines and clones. Infect Immun (1986) 1.16
Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother (1998) 1.15
Dysphagia in treated nasopharyngeal cancer. Head Neck (2000) 1.13
Assessment of quantitative methods for determination of trichothecenes in grains and grain products. J Assoc Off Anal Chem (1982) 1.11
Acute toxicity studies on roquefortine and PR toxin, metabolites of Penicillium roqueforti, in the mouse. Food Cosmet Toxicol (1978) 1.11
New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat. Antimicrob Agents Chemother (1995) 1.11
Unilateral dermatomal superficial telangiectasia. Nine new cases and a review of unilateral dermatomal superficial telangiectasia. J Am Acad Dermatol (1983) 1.10
Search for a W' or techni-ρ decaying into WZ in pp Collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2012) 1.10
Trace element contamination in benthic macroinvertebrates from a small stream near a uranium mill tailings site. Environ Monit Assess (2002) 1.10
Evidence for an excess of B→D*τ(-)ν(τ) decays. Phys Rev Lett (2012) 1.10
Search for new physics with same-sign isolated dilepton events with jets and missing transverse energy. Phys Rev Lett (2012) 1.09
Observation of time-reversal violation in the B0 meson system. Phys Rev Lett (2012) 1.09
Nontransmission of deoxynivalenol (vomitoxin) to eggs and meat in chickens fed deoxynivalenol-contaminated diets. J Agric Food Chem (1984) 1.09
Economic burden of obesity-related chronic diseases in Mainland China. Obes Rev (2008) 1.08